The IQ Working Group has defined a pragmatic risk-based approach to audit trail review, where it is only required for high impact GxP data.
Leverage artificial intelligence (AI) for a more streamlined GMP manufacturing process.
Life sciences data sets can be vast and complex to process, but up to now bringing intelligent automation systems up to speed and validating them has felt debilitatingly onerous. Large language models tackle these barriers head on. Ramesh Ramani and RaviKanth Valigari, technology innovators at ArisGlobal, explain.
Although the European Generic medicines Association (EGA) n has welcomed the European Commission's proposal for a Directive on the falsification of medicines, it has also identified subjects that are of specific relevance to the European generic medicines industry.
It analizes how to optimize a bio-decontamination process using an atomized hydrogen peroxide new cycle development method for use in pharmaceutical aseptic enclosures.
Regulatory, analytical, and process concerns must be taken into account.
Legislation has prompted the pharma industry to seek technologies that can be used to secure a product throughout the supply chain.
Maintaining a quality culture across the diverse functions in a bio/pharmaceutical company is difficult. Representatives of the Quality Coordinating Committee of IQ Consortium report on collaborative efforts to address data integrity and the modernization of FDA’s good laboratory practice regulations.
One of the main purposes of stability testing is to establish shelf life for these drug products. The goal of this paper is to create an Excel spreadsheet, which can be used for statistical testing of more than three stability batches for poolability.
The root cause of the most serious integrity issues has generally been a lapse of ethical behavior on the part of an individual.
We demonstrate the wide range of customized products and services that Actylis offers its biopharma customers.
Emerging new technologies and disruptive manufacturing concepts are providing new opportunities for pharmaceutical companies.
Recombinant microbial whole-cell biocatalysis is a valuable approach for producing enantiomerically pure intermediates. The authors examine several groups of enzymes using this approach: dehydrogenases, hydantoinases, and acylases.
Experts Susan J. Schniepp, distinguished fellow for Regulatory Compliance Associates, and Steven J. Lynn, executive vice-president, Pharmaceuticals for Regulatory Compliance Associates, discuss the verification of compendial methods.
For a pharmaceutical manufacturer, choosing the QMS that is right for you can be a daunting task. This guide offers a review of the obstacles most likely to hinder a quick, smooth, and effective QMS implementation.
The authors studied the effect of the combination of binders on the flow and compressibility characteristics of the agglomerates of binary combination of lactose and dibasic calcium phosphate dihydrate.
Regulatory, analytical, and process concerns must be taken into account.
For the pharmaceutical industry, drug formulation is a cornerstone, crucial for converting bioactive molecules into effective, stable, and patient-friendly medications.
Webinar Date/Time: Thu, Mar 14, 2024 2:00 PM EDT
Laks Pernenkil, principal and practice leader, US Life Sciences Product & Supply Operations, Deloitte, discusses the impact that digitalization is having on data generation and data integrity in bio/pharma manufacturing.
The authors evaluated the effect of polymer composition on the drug-release profile and the effect of storage conditions on dissolution characteristics.
The degree of formality in a risk management process should be customized to the organization’s particular needs and the risks involved.
Research suggests that intranasal nanosuspensions offer a promising way to formulate and deliver drugs that are poorly soluble in water to patients with chronic conditions.
The authors focus on how single-use systems effectively control three potential sources of common contamination: cross contamination, microbial contamination and biologic contamination of the process facility.
Analytical procedure performance can be continually verified by risk-based monitoring of performance related data.
Developing bioassay methods requires a new approach for cell and gene therapy drug development.